Retatrutide: The Triple-Agonist That Redefined Weight Loss
A single molecule that activates three metabolic hormone pathways — GLP-1, GIP, and glucagon — delivering the largest average weight loss seen in a phase 3 obesity trial to date.
What is Retatrutide?
Retatrutide (LY3437943) is an investigational triple-agonist peptide from Eli Lilly that simultaneously activates the GLP-1, GIP, and glucagon receptors. In the pivotal TRIUMPH-1 phase 3 trial, participants on the 12 mg dose lost an average of 28.3% of body weight (about 70 lbs) over 80 weeks, with 45.3% achieving 30% or greater weight loss — results that exceed every previously approved agent.
Why retatrutide is different
Semaglutide targets one receptor (GLP-1). Tirzepatide targets two (GLP-1 and GIP). Retatrutide targets three — adding glucagon-receptor activation, which increases energy expenditure on top of appetite suppression and improved insulin response.
This "triple-G" mechanism is why retatrutide has produced the highest average weight-loss numbers reported in a phase 3 obesity program, positioning it as a potential next-generation standard if it secures approval.
TRIUMPH-1 phase 3 results
- Participants on 12 mg lost an average of 28.3% body weight (~70.3 lbs) over 80 weeks.
- 45.3% of participants achieved 30% or greater total weight loss.
- Dose-dependent results showed escalating efficacy across the tested range.
- Improvements were reported across cardiometabolic markers alongside weight reduction.
The mechanism, explained simply
GLP-1 reduces appetite and slows digestion. GIP enhances insulin signaling and may improve how the body handles fat. Glucagon — counterintuitively — raises energy expenditure and mobilizes stored fat when paired with the appetite-suppressing partners.
By combining all three in balanced ratios, retatrutide aims to drive weight loss from both sides of the energy equation: eating less and burning more.
Safety, rapid weight loss, and open questions
The most powerful GLP-1-class drugs also raise new questions. Scientists are actively studying how very rapid weight loss affects lean mass, bone, and long-term metabolic health.
Gastrointestinal side effects and treatment discontinuations were notable, particularly at higher doses. Retatrutide is still investigational and not approved — meaning it should never be sourced or used outside of a regulated clinical trial.
A caution on grey-market sourcing
Because retatrutide is generating intense online interest, unregulated "research-only" versions are circulating. These carry serious risks: unknown purity, incorrect dosing, contamination, and no medical oversight.
No clinical-trial result transfers to an unverified vial bought online. Evidence applies only to the regulated compound studied under medical supervision.
12 mg retatrutide over 80 weeks in the TRIUMPH-1 phase 3 trial.
Frequently asked questions
What makes retatrutide a "triple agonist"?
It activates three receptors at once — GLP-1, GIP, and glucagon. Most weight-loss drugs activate only one or two. The added glucagon activity increases energy expenditure.
How much weight did people lose in trials?
In TRIUMPH-1, participants on 12 mg lost an average of 28.3% (about 70 lbs) over 80 weeks, with 45.3% losing 30% or more.
Is retatrutide FDA approved?
Not yet. As of 2026 it is investigational and in phase 3 trials. It is not available as an approved prescription drug.
How does retatrutide compare to tirzepatide?
Tirzepatide is a dual agonist (GLP-1/GIP); retatrutide adds glucagon as a third target. In trials retatrutide has produced higher average weight loss, but head-to-head approved comparisons are still ongoing.
Is it safe to buy retatrutide online?
No. Unregulated retatrutide carries serious risks of unknown purity, contamination, and incorrect dosing. Clinical-trial safety data do not apply to grey-market products.
This page is educational research information only and is not medical advice or an endorsement to obtain or use any substance. Retatrutide is investigational and not FDA approved. Do not source or use unregulated peptides. Consult a licensed clinician.
Go deeper into the data
Track clinical trials, compare metabolic peptides side by side, and read the evidence scoring methodology.